Clinical effect of Meniere's disease by ibudilast.

概要

論文の詳細を見る
Allergy and blood-flow disturbances are important pathogenetic factors in Meniere's disease. Ibudilast is a new anti-allergic agent, selectively antagonistic for and exhibiting inhibitory activity against slow-reacting substances of anaphylaxis (SRS-A) and/or leukotriene. This new agent is also a cerebral vasodilator with anti-thrombotic effects.The therapeutic effects of ibudilast were studied in 22 Patients with Meniere's disease. The Patients were given a 10mg capsule of Ibudilast 3 times daily for 4 weeks.Seventeen of 22 Cases (77%) were relieved of dizziness after administration for 2 weeks, and 20 of 22 Cases (91%) after 4 weeks. Ten of 21 Cases (48%) were relieved of tinnitus after 2 weeks, and 12 of 21 Cases (57%) after 4 weeks. Fifteen of 20 Cases (75%) were relieved of numbness after 2 weeks and 17 of 20 Cases (85%) after 4 weeks. Hearing at over 10dB in 15 of 24 ears (63%) improved after 2 weeks and in 17 of 24 ears (71%) after 4 weeks.The results suggest that ibudilast is a clinically useful drug in the treatment of dizziness, tinnitus, numbness, and hearing disturbances in patients affected by Meniere's disease.
耳鼻咽喉科臨床学会の論文